Please enable Javascript
Roundtable Renal Cell Carcinoma
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
View More
RCC Panel Discusses Treatment Response, Dosing, Patient Management, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
View More
LITESPARK-005 Study Results and Thoughts on Second-Line RCC Treatment
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
View More
CheckMate 67T Offers a Look at a Different Treatment Route of Administration
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
View More
Panel Discusses Other RCC Treatment Options: Radiation Techniques, Surgery, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
View More
CheckMate 9ER: Frontline Nivolumab/Cabozantinib in RCC Patients With Metastases, QOL Considerations
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
View More
RCC Panel Reacts to Long-Term Follow-Up From CheckMate 214
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
View More
ASCO GU Data Updates: KEYNOTE-564 and CheckMate 914
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
View More
Looking Ahead in RCC: Belzutifan, Triplets, Treatment Combinations, and More
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
View More
CheckMate 67T and the Potential of Subcutaneous Nivolumab Administration
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
View More
CheckMate 9ER: What Is the Impact for RCC?
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
View More
Panel Shares Thoughts on RCC Data: CheckMate 914, 214 and IMDC Selection Criteria
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
View More
Panel Discussion on OS Data From KEYNOTE-564 Study and Post-Relapse Treatment Selection
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
View More
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
View More
Frontline RCC Treatment Selection: IO/IO Versus IO/TKI
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
View More
What’s on the Horizon for RCC Treatment and Care?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
View More
RCC Highlights From ASCO GU: Adjuvant Treatment, Immunotherapy, Toxicities, and More
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
View More
KEYNOTE-B61 Study Results and a Focus on Non-Clear Cell Kidney Cancer
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
View More
Longer-Term Follow-Up on Frontline IO and TKI Studies and Impacts to Treatment Selection
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
View More
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
View More
Load More
Advertisement
Advertisement